BIONTECH SE-ADR (22UA.DE) Stock Price, Forecast & Analysis
Europe - FRA:22UA - US09075V1026 - ADR
22UA.DE Key Statistics, Chart & Performance
The current stock price of 22UA.DE is 87.15 EUR. In the past month the price decreased by -1.53%. In the past year, price decreased by -16.6%.
22UA.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.74 | 44.96B | ||
| 1AE.DE | ARGENX SE | 67.72 | 44.95B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.90B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.17 | 1.01B | ||
| NANO.PA | NANOBIOTIX | N/A | 820.61M | ||
| PHIL.MI | PHILOGEN SPA | 20.79 | 692.99M | ||
| IVA.PA | INVENTIVA SA | N/A | 517.80M | ||
| FYB.DE | FORMYCON AG | N/A | 341.03M | ||
| VLA.PA | VALNEVA SE | N/A | 314.28M | ||
| AYJ.DE | VALNEVA SE | N/A | 312.22M |
Related stock screener links
About 22UA.DE
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ DE
Employees: 6772
Phone: 4949613190840
BIONTECH SE-ADR / 22UA.DE FAQ
What does BIONTECH SE-ADR do?
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Can you provide the latest stock price for BIONTECH SE-ADR?
The current stock price of 22UA.DE is 87.15 EUR. The price decreased by -1.86% in the last trading session.
What is the dividend status of BIONTECH SE-ADR?
22UA.DE does not pay a dividend.
How is the ChartMill rating for BIONTECH SE-ADR?
22UA.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists 22UA stock?
22UA.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the employee count for 22UA stock?
BIONTECH SE-ADR (22UA.DE) currently has 6772 employees.
22UA.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 22UA.DE. When comparing the yearly performance of all stocks, 22UA.DE is a bad performer in the overall market: 89.29% of all stocks are doing better.
22UA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 22UA.DE. 22UA.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
22UA.DE Financial Highlights
Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 31.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.6% | ||
| ROE | -1.87% | ||
| Debt/Equity | 0.01 |
22UA.DE Forecast & Estimates
29 analysts have analysed 22UA.DE and the average price target is 120.48 EUR. This implies a price increase of 38.24% is expected in the next year compared to the current price of 87.15.
For the next year, analysts expect an EPS growth of -75.93% and a revenue growth -17.74% for 22UA.DE